|By Marketwired .||
|December 26, 2013 11:06 AM EST||
MONTREAL, QUEBEC -- (Marketwired) -- 12/26/13 -- December 26, 2013 - Pediapharm Inc. (TSX VENTURE: PDP) ("Pediapharm") is pleased to announce that it has successfully met the necessary requirements to begin trading on the TSX Venture Exchange. The common shares of Pediapharm will begin trading on December 27, 2013, at market open under the ticker symbol "PDP". In connection with the listing on the TSX Venture Exchange, on December 10, 2013, Pediapharm announced it had received gross proceeds of $6,967,490 from its equity financing activities.
"The entire board of Pediapharm views the listing of TSX Venture as a strong signal about the capabilities of the team and the robustness of the business model. The Company will now have the financial means to substantially accelerate its growth by continuing to build its product pipeline through licensing and acquisition. This is excellent news for Canadian children as they will now have access to a greater number of innovative therapies" said Pierre Lapalme, Chairman of Pediapharm.
Sylvain Chretien, President and CEO of Pediapharm commented: "The Pediapharm team is highly motivated to execute its business plan with the ultimate objective of creating value for the shareholders of Pediapharm."
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Pediapharm is the only Canadian specialty pharmaceutical company, dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice and its eggs; EpiCeram® a non-steroid emulsion for eczema; KoolEffect which reduces the symptoms of fever; and VapoLyptus; a soothing vapour patch of eucalyptus and camphor.
Caution concerning forward-looking statements
This news release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Pediapharm Inc. The forward-looking statements or information contained in this news release are made as of the date hereof and Pediapharm Inc. does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.